Search | Clinical Trials Finder

Conditions: PTSD, Posttraumatic Stress Disorder
Interventions: Ketamine, Placebo/Saline; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: West Haven, Connecticut • Minneapolis, Minnesota • San Antonio, Texas

Conditions: Autism Disorder
Interventions: STX209 (15mg), placebo, STX209 (30mg); Drug
Lead sponsor: Timothy Roberts; Other
Eligibility: 14 Years to 17 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: Interferon alfa-n3, Interferon alfa-n1; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 15
States / cities: Los Angeles, California • Redwood City, California • New Haven, Connecticut + 9 more

Conditions: Dry Eye Disease, Dry Eye Syndrome
Interventions: AGN-242428, AGN-231868, AGN-242428 Vehicle, AGN-231868 Vehicle, Lifitegrast 5% Ophthalmic Solution; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 11
States / cities: Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 8 more

Conditions: Osteoporosis
Interventions: Teriparatide, Risedronate, Placebo, Calcium, Vitamin D; Drug · Dietary Supplement
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 6
States / cities: Fort Lauderdale, Florida • New Port Richey, Florida • Orlando, Florida + 3 more

Conditions: Acute Pain, Postoperative
Interventions: LTG-001 High Dose, LTG-001 Mid Dose, LTG-001 Low Dose, Placebo, Suzetrigine; Drug · Other
Lead sponsor: Latigo Biotherapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Obesity, Overweight, Overweight With One Weight Related Comorbidity
Interventions: RO7204239, RO7204239 Matching Placebo, Tirzepatide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Anniston, Alabama • Spring Valley, California • Clermont, Florida + 16 more

Conditions: Cirrhosis, Liver, Advanced Liver Fibrosis
Interventions: erlotinib hydrochloride, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Ulcerative Colitis
Interventions: GB004, Placebo; Drug
Lead sponsor: GB004, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Monroe, Louisiana

Conditions: Alzheimer's Disease, Dementia
Interventions: Drug: EVP-6124, Placebo; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 44
States / cities: Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 41 more

Conditions: Non-small Cell Lung Cancer
Interventions: Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo; Biological · Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 1,513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 49
States / cities: Fort Smith, Arkansas • Anaheim, California • Glendale, California + 41 more

Conditions: Malaria
Interventions: Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp), Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp), Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Schizophrenia, Impaired Cognition
Interventions: EVP-6124, Placebo; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 753 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 38
States / cities: Tucson, Arizona • Anaheim, California • Bellflower, California + 35 more

Conditions: Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease
Interventions: SPR720, Placebo, Open-label Standard of Care; Drug
Lead sponsor: Spero Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Altamonte Springs, Florida • Atlantis, Florida • Clearwater, Florida + 6 more

Conditions: Chronic Hepatitis B Virus Infection, Hepatitis B
Interventions: Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 5
States / cities: San Francisco, California • San Jose, California • Minneapolis, Minnesota + 2 more

Conditions: Epilepsy
Interventions: Vinpocetine; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Precancerous Condition
Interventions: perillyl alcohol, placebo; Drug · Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Alcoholism
Interventions: Ethanol High Dose, Ethanol Low Dose, and Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 30 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2015
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Influenza
Interventions: NasoVAX; Biological
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Papulopustular Rosacea
Interventions: omiganan, placebo; Drug
Lead sponsor: Maruho Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 17
States / cities: Birmingham, Alabama • Santa Monica, California • New Haven, Connecticut + 14 more

Conditions: Borderline Personality Disorder
Interventions: Ketamine, Midazolam; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Bullous Pemphigoid
Interventions: nomacopan (rVA576), Placebo; Drug · Other
Lead sponsor: AKARI Therapeutics; Industry
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 7
States / cities: Los Angeles, California • Skokie, Illinois • Indianapolis, Indiana + 4 more

Conditions: Schizophrenia
Interventions: Samidorphan (Low Dose), Samidorphan (Medium Dose), Samidorphan (High Dose), Placebo, Olanzapine; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 50
States / cities: Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 43 more

Conditions: Bronchopulmonary Dysplasia, Respiratory Distress Syndrome, Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Interventions: Minimal mechanical ventilation management, Routine mechanical ventilation management, Dexamethasone, Placebo; Procedure · Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 5 Minutes to 10 Days
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 13
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 10 more

Search by objective public record fields.

CAP-Ketamine for Antidepressant Resistant PTSD

MEG Study of Acute STX209 Effects in ASD

A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease

A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture

This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

Erlotinib for Hepatocellular Carcinoma Chemoprevention

GB004 in Adult Subjects With Active Ulcerative Colitis

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Cognitive Effects of Vinpocetine in Healthy Adults and Patients With Epilepsy

Topical Perillyl Alcohol in Treating Patients With Sun Damaged Skin and Actinic Keratoses

Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

A Twelve Week Safety and Efficacy Study in Rosacea

Ketamine in Borderline Personality Disorder

Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)

A Study of ALKS 3831 in Adults With Schizophrenia

Minimal Breathing Support and Early Steroids to Prevent Chronic Lung Disease in Extremely Premature Infants (SAVE)